Home / Knowledge hub /
From vial to value: How GLP-1s are redefining injectable care for chronic conditions
October 3, 2025
The market for glucagon-like peptide-1 (GLP-1) therapies is growing rapidly, with a projected value of $186.6 billion by 2032. Originally developed for diabetes, these therapies are now widely used for obesity treatment, which has created a need for convenient and scalable delivery systems. This growth is reshaping the industry, creating new demands on manufacturing capacity and requiring innovative solutions for at-home care.
The shift to self-administration
GLP-1 therapies are changing patient expectations for injectable treatments. Patients now expect at-home administration, simple instructions, minimal pain and less frequent dosing. This has led to a significant shift from traditional vial-based delivery to more patient-friendly options like prefilled syringes and autoinjectors. These devices simplify dosing and are designed for ease of use, eliminating the need for clinical oversight.
As patients transition to at-home care, the manufacturing of these products becomes more complex. Devices must be intuitive, compatible with various formulations and meet strict standards for sterility and reliability. Manufacturers are challenged to act as both product developers and regulatory strategists to ensure these devices meet all necessary standards.
With the accelerated adoption of GLP-1s, contract development and manufacturing organizations (CDMOs) have become essential strategic partners for navigating the evolving landscape. They are critical for meeting the unprecedented demand for prefilled syringes and autoinjectors, which has outpaced market preparation and created a significant capacity shortfall.
By reading this comprehensive whitepaper, you will learn:
- Why the shift from vial-based delivery to prefilled syringes and autoinjectors is creating new capacity demands
- The details of the device formats, both approved and in development, that are best suited for self-administered chronic care
- What combination product compliance looks like under evolving global regulations.
Ready to navigate the future of chronic care?
Download the full whitepaper to learn more about how GLP-1s are reshaping injectable manufacturing, device design and patient expectations.
Get Your Copy Now
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
A bridge to the future: Our world-class Bridgeton facility
Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging. A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, […]
Learn More
Sterile product introduction and tech transfers in a crowded market
The tech transfer landscape for sterile products is increasingly complex, with pressure to reduce time to market. Find out how to navigate common challenges and avoid costly delays or oversights in this presentation from our Director, Client Portfolio & Relationship Management, Kim Brown. Download your copy to explore: Benefits of a commercial manufacturing mindset How […]
Learn More
Aseptic injectable fill-finish facility
Through strategic investments and expansions, Kindeva Drug Delivery is on the forefront of combination product innovation. Our aseptic injectable fill-finish facility in Bridgeton, Missouri, is one example of our commitment to excellence. With the addition of this facility, we are one of only a few CDMOs capable of servicing sterile fill, device manufacture, and final […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.